Form 13-F position report

MIRATI THERAPEUTICS INC

Reported by VANGUARD GROUP INC

MRTX CUSIP 60468T105 Manager CIK 0000102909

Reported 0 shares, down 5,306,693 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 43 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 717265000
2021-06-30 667834000
2021-09-30 732028000
2021-12-31 651154000
2022-03-31 368577000
2022-06-30 305308000
2022-09-30 330225000
2022-12-31 225366865
2023-03-31 187735762
2023-06-30 179865075
2023-09-30 248275969
2023-12-31 311768213
2024-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for MIRATI THERAPEUTICS INC held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2024 Reduced 0 -5,306,693 (-100.0%) 0 $0 2024-05-10
Q4 2023 Reduced 5,306,693 -392,939 (-6.9%) < 0.01% $311,768,213 2024-02-14
Q3 2023 Added 5,699,632 +721,357 (14.5%) < 0.01% $248,275,969 2023-11-14
Q2 2023 Reduced 4,978,275 -71,100 (-1.4%) < 0.01% $179,865,075 2023-08-14
Q1 2023 Added 5,049,375 +75,487 (1.5%) < 0.01% $187,735,762 2023-05-15
Q4 2022 Added 4,973,888 +245,589 (5.2%) < 0.01% $225,366,865 2023-02-10
Q3 2022 Added 4,728,299 +180,278 (4.0%) < 0.01% $330,225,000 2022-11-14
Q2 2022 Added 4,548,021 +65,211 (1.5%) < 0.01% $305,308,000 2022-08-12
Q1 2022 Added 4,482,810 +43,833 (1.0%) < 0.01% $368,577,000 2022-05-13
Q4 2021 Added 4,438,977 +301,120 (7.3%) 0.01% $651,154,000 2022-02-14
Q3 2021 Added 4,137,857 +3,434 (0.1%) 0.02% $732,028,000 2021-11-12
Q2 2021 Reduced 4,134,423 -52,762 (-1.3%) 0.02% $667,834,000 2021-08-13
Q1 2021 Added 4,187,185 +154,947 (3.8%) 0.02% $717,265,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

214 managers reported MIRATI THERAPEUTICS INC for Q1 2024.

Managers reporting MIRATI THERAPEUTICS INC in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Sachetta LLC Unchanged 24 0 < 0.01% $1,410 2 qtrs
IFP Advisors Inc Reduced 19 -3,659 < 0.01% $1,115 9 qtrs
State of New Jersey Common Pension Fund D Reduced 0 -44,027 0 $0 19 qtrs
NATIXIS Reduced 0 -215,731 0 $0 7 qtrs
TANG CAPITAL MANAGEMENT LLC Reduced 0 -1,558,059 0 $0 7 qtrs
LAZARD ASSET MANAGEMENT LLC Reduced 0 -1,294 0 $0 2 qtrs
Farther Finance Advisors LLC Reduced 0 -58 0 $0 4 qtrs
BOOTHBAY FUND MANAGEMENT LLC Reduced 0 -10,000 0 $0 2 qtrs
CENTRAL TRUST Co Reduced 0 -15 0 $0 3 qtrs
Allspring Global Investments Holdings LLC Reduced 0 -43 0 $0 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 10, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.